Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Bid, Hemant K ^a   Oswald, Duane ^a   Li, Chenglong ^b   London, Cheryl A ^b   Lin, Jiayuh ^a   Houghton, Peter J ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 1; GELATINASE B; KI 67 ANTIGEN; LLL 12; PROTEIN INHIBITOR; STAT3 PROTEIN; THROMBOPLASTIN; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MICROVASCULATURE; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SCID MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTHRAQUINONES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, SCID; MICROTUBULES; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOSARCOMA; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84859828700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035513     Document Type: Article

References (26)

1. Buettner R, Mora LB, Jove R, (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 945-954.
2. Lai R, Navid F, Rodriguez-Galindo C, Liu T, Fuller CE, et al. (2006) STAT3 is activated in a subset of the Ewing sarcoma family of tumours. The Journal of pathology 208: 624-632.
3. Chen CL, Loy A, Cen L, Chan C, Hsieh FC, et al. (2007) Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC cancer 7: 111.
4. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, et al. (2009) Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC cancer 9: 81.
5. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, et al. (2008) Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric blood & cancer 51: 42-48.
6. Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, et al. (2002) Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. The Journal of biological chemistry 277: 6676-6681.
7. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
8. Wei D, Le X, Zheng L, Wang L, Frey JA, et al. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329.
9. Chen Z, Han ZC, (2008) STAT3: a critical transcription activator in angiogenesis. Medicinal research reviews 28: 185-200.
10. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, et al. (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proceedings of the National Academy of Sciences of the United States of America 101: 10602-10607.
11. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, et al. (2003) Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. The Journal of biological chemistry 278: 40026-40031.
12. Song H, Wang R, Wang S, Lin J, (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 102: 4700-4705.
13. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
14. Lin L, Hutzen B, Li PK, Ball S, Zuo M, et al. (2010) A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12: 39-50.
15. Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, et al. (2003) VEGF differentially activates STAT3 in microvascular endothelial cells. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 17: 1562-1564.
16. Teng TS, Lin B, Manser E, Ng DC, Cao X, (2009) Stat3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIX. Journal of cell science 122: 4150-4159.
17. Verma NK, Dourlat J, Davies AM, Long A, Liu WQ, et al. (2009) STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. The Journal of biological chemistry 284: 12349-12362.
18. Neale G, Su X, Morton CL, Phelps D, Gorlick R, et al. (2008) Molecular characterization of the pediatric preclinical testing panel. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 4572-4583.
19. Ball S, Li C, Li PK, Lin J, (2011) The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PloS one 6: e18820.
20. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, et al. (2006) Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 7140-7148.
21. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, et al. (2010) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer research 70: 2445-2454.
22. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, et al. (2008) Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric blood & cancer 50: 581-587.
23. Thaloor D, Singh AK, Sidhu GS, Prasad PV, Kleinman HK, et al. (1998) Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research 9: 305-312.
24. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, et al. (2009) The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113: 254-263.
25. Meyer WH, Houghton JA, Houghton PJ, Webber BL, Douglass EC, et al. (1990) Development and characterization of pediatric osteosarcoma xenografts. Cancer research 50: 2781-2785.
26. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, et al. (2007) The pediatric preclinical testing program: description of models and early testing results. Pediatric blood & cancer 49: 928-940.